Dialysis News and Research

Latest Dialysis News and Research

Fresenius third quarter net revenue increases 6% to $3,058 million

Fresenius Medical Care AG & Co. KGaA: Net revenue for the third quarter of 2010 increased by 6% to $3,058 million compared to the third quarter of 2009. Organic revenue growth worldwide was 6%.

2 Nov 2010

Access to kidney transplantation increases for elderly patients

Elderly patients with kidney failure get kidney transplants more often than they did a decade ago, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN). The results suggest that the chances of receiving a kidney transplant are better than ever for an older patient who needs one.

29 Oct 2010

Rockwell receives SFP patent for GMP formulation

Rockwell Medical a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia, announced today that it has received notice from the U.S. Patent and Trademark Office for patent issuance on its proprietary GMP formulation for Soluble Ferric Pyrophosphate (SFP), the Company's lead-drug candidate for treating iron deficiency anemia in ESRD patients.

27 Oct 2010

Keryx completes randomization of last patient in Zerenex Phase 3 study for hyperphosphatemia

Keryx Biopharmaceuticals reported today the randomization of the last patient in its short-term study component of its Phase 3 registration program of Zerenex™ (ferric citrate), the Company's iron-based phosphate binder for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease on dialysis.

26 Oct 2010

Tengion presents data on Neo-Kidney Augment at Transplantation's Annual Scientific Exchange

Tengion, Inc. a leader in regenerative medicine, presented new data on Saturday, October 23, 2010 in a podium presentation at the American Society for Transplantation's Annual Scientific Exchange in Orlando, FL. The presentation highlighted new early data from Tengion's Neo-Kidney Augment development program demonstrating promising improvements in kidney function with an autologous cellular therapy approach to kidney regeneration in a canine model of chronic kidney disease.

26 Oct 2010

Amgen reports $3,816 million for 2010 third quarter revenue

Amgen reported revenue unchanged for the third quarter of 2010 at $3,816 million versus $3,812 million for the third quarter of 2009.

26 Oct 2010

72% of patients misdiagnosed with pneumonia upon readmission : Study

Patients were misdiagnosed with pneumonia at an alarming rate when they were readmitted to the hospital shortly after a previous hospitalization for the same illness, according to two Henry Ford Hospital companion studies.

25 Oct 2010

Social networks important for maintaining dialysis patients' health: Study

Dialysis patients with little social support from friends and family are more likely to ignore doctors' orders, experience a poorer quality of life, and die prematurely, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology. The results suggest strong social networks are important for maintaining dialysis patients' health.

22 Oct 2010

Baxter third quarter net income increases 12% to $595 million

Baxter International Inc. today announced its financial results for the third quarter of 2010, and provided its fourth quarter and updated full-year 2010 financial outlook.

From Baxter International Inc. 21 Oct 2010

Alexion 2010 third quarter revenue increases from $102.6 to $141.6 million

Alexion Pharmaceuticals, Inc. today announced financial results for the three and nine months ended September 30, 2010.

21 Oct 2010

Alexion announces results of eculizumab two open-label Phase 2 studies for aHUS treatment

Alexion Pharmaceuticals, Inc. today announced that its two open-label Phase 2 studies investigating eculizumab (Soliris) as a treatment for patients with atypical Hemolytic Uremic Syndrome (aHUS) have met the primary and key secondary endpoints with high clinical and statistical significance, in interim analyses.

21 Oct 2010

Abbott third quarter worldwide sales increase 11.8% to $8.7 billion

Abbott today announced financial results for the third quarter ended Sept. 30, 2010.

20 Oct 2010

Rockwell Medical announces design of Phase III development program for Soluble Ferric Pyrophosphate

Rockwell Medical, a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron-deficiency anemia, announced today the design of its Phase III development program for Soluble Ferric Pyrophosphate (SFP) as a continuous iron replacement therapeutic.

20 Oct 2010

Aspirin before cardiac surgery reduces postoperative cardiocerebral complications

A study presented at the American Society of Anesthesiologists 2010 Annual Meeting revealed that use of aspirin before cardiac surgery reduced postoperative cardiocerebral complications, including stroke, myocardial ischemia, heart block and cardiac arrest by more than 33 percent when compared to patients who did not use aspirin.

20 Oct 2010

New book focuses on clinical importance of online HDF technique

Hemodiafiltration (HDF) for the treatment of end-stage renal disease patients is predominantly performed in European countries and in Japan, with some differences in technique such as rate of blood flow and dialysis fluid delivery systems.

20 Oct 2010

Amgen to review study results of ESA in chronic renal failure patients with FDA and CRDAC

Amgen will review the results from TREAT (the Trial to Reduce Cardiovascular Events with Aranesp® Therapy) and will discuss how these results inform the appropriate use of erythropoiesis-stimulating agents (ESAs) for chronic renal failure (CRF) patients at today's meeting of the Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC).

19 Oct 2010

New data on Merck’s odanacatib for osteoporosis in postmenopausal women presented at 32nd ASBMR

New data on odanacatib, an investigational cathepsin-K (Cat-K) inhibitor in development for the treatment of osteoporosis in postmenopausal women, were presented at the 32nd Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) in Toronto, Canada.

19 Oct 2010

BARACLUDE sNDA receives FDA approval for treatment of CHB patients with decompensated liver disease

Bristol-Myers Squibb Company announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) of BARACLUDE for the treatment of chronic hepatitis B (CHB) in adult patients with decompensated liver disease.

18 Oct 2010

FDA plans to revoke knee implant approval following intense political pressure for its approval

The Food and Drug Administration on Thursday said it planned to revoke a medical-device company's right to sell a knee implant called Menaflex after an unprecedented yearlong review concluded the agency erred in allowing it on the market

18 Oct 2010

Crosstex International introduces customized surgical masks

Cantel Medical Corp., announced today the launch of a new, unique design of medical face masks - the SecureFit™ series by Crosstex International, a Cantel subsidiary and a leading U.S. manufacturer of medical face masks. The SecureFit™ series of masks addresses scientific research that points to poorly fitting masks as a major hindrance to their effectiveness.

15 Oct 2010

Dialysis News and Research

Latest Dialysis News and Research

Fresenius third quarter net revenue increases 6% to $3,058 million

Access to kidney transplantation increases for elderly patients

Rockwell receives SFP patent for GMP formulation

Keryx completes randomization of last patient in Zerenex Phase 3 study for hyperphosphatemia

Tengion presents data on Neo-Kidney Augment at Transplantation's Annual Scientific Exchange

Amgen reports $3,816 million for 2010 third quarter revenue

72% of patients misdiagnosed with pneumonia upon readmission : Study

Social networks important for maintaining dialysis patients' health: Study

Baxter third quarter net income increases 12% to $595 million

Alexion 2010 third quarter revenue increases from $102.6 to $141.6 million

Alexion announces results of eculizumab two open-label Phase 2 studies for aHUS treatment

Abbott third quarter worldwide sales increase 11.8% to $8.7 billion

Rockwell Medical announces design of Phase III development program for Soluble Ferric Pyrophosphate

Aspirin before cardiac surgery reduces postoperative cardiocerebral complications

New book focuses on clinical importance of online HDF technique

Amgen to review study results of ESA in chronic renal failure patients with FDA and CRDAC

New data on Merck’s odanacatib for osteoporosis in postmenopausal women presented at 32nd ASBMR

BARACLUDE sNDA receives FDA approval for treatment of CHB patients with decompensated liver disease

FDA plans to revoke knee implant approval following intense political pressure for its approval

Crosstex International introduces customized surgical masks

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Dialysis News and Research

Latest Dialysis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in